The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

Compass Pathways (CMPS), on Wednesday, said the U.S. Food and Drug Administration (FDA) has accepted its Investigational New ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

Shares of Compass Pathways Plc continue to trade within highly speculative territory, closing the week at $5.23 with a marginal gain of $0.01. Beneath this surface-level stability lies a fundamental ...

Fintel reports that on November 5, 2025, Morgan Stanley maintained coverage of COMPASS Pathways plc - Depositary Receipt (NasdaqGS:CMPS) with a Overweight recommendation. As of October 30, 2025, the ...

The recent earnings call for Compass Pathways Plc painted a generally positive picture, underscoring significant progress in clinical trials, regulatory interactions, and launch preparations. Despite ...

Investing.com - Oppenheimer has upgraded Compass Pathways (NASDAQ:CMPS) from Perform to Outperform, setting a price target of $15.00 based on the potential of its psilocybin therapy for ...

Completion of enrollment for the second phase three trial (006), with data disclosures planned for Q1 2026. Collaborative discussions with the FDA could expedite the review process. Commercial efforts ...

Mental health treatments often fail many patients, leaving them struggling to find relief and support. Patients in this category are often considered “treatment-resistant,” where multiple therapies ...